4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)
SVB Leerink resumed coverage of Pandion Therapeutics with a rating of Market Perform and set a new price target of $60.00
Morgan Stanley resumed coverage of Pandion Therapeutics with a rating of Equal Weight and set a new price target of $60.00 from $25.00 previously
Morgan Stanley downgraded Pandion Therapeutics from Overweight to Equal-Weight and set a new price target of $60.00 from $25.00 previously
SVB Leerink downgraded Pandion Therapeutics from Outperform to Market Perform and set a new price target of $60.00
Morgan Stanley downgraded Pandion Therapeutics from Overweight to Equal Weight
15-12B - Pandion Therapeutics, Inc. (0001807901) (Filer)
EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)
EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)
S-8 POS - Pandion Therapeutics, Inc. (0001807901) (Filer)
S-8 POS - Pandion Therapeutics, Inc. (0001807901) (Filer)
POS AM - Pandion Therapeutics, Inc. (0001807901) (Filer)
POS AM - Pandion Therapeutics, Inc. (0001807901) (Filer)
8-K - Pandion Therapeutics, Inc. (0001807901) (Filer)
SC 14D9/A - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC TO-T/A - Pandion Therapeutics, Inc. (0001807901) (Subject)
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND). On Feb. 25, 2021, Merck announced its intent to acquire Pandion. Upon the successful closing of the tender offer, stockholders of Pandion will receive $60 in cash for each share of Pandion common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Pandion will become a subsidiary of Merck. Merck will
KENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational charac
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today presented preclinical data on PT001, the Company’s tissue-tethered PD-1 agonist, at the Network for Pancreatic Organ Donors with Diabetes (nPOD) 13th Annual Scientific Meeting. The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes. PD-1 plays a critical role in
WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET. A live webcast of the presentation will be available in the Investors and News section of Pandion Therapeutics’ website at https://www.pandiontx.com/. A replay of the webcast will be available shortly following the presentation. About Pa
-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases-PT101 maintained selectivity for regulatory T cells at all doses tested-Phase 1a/2b clinical trial in ulcerative colitis expected to start mid-2021 and Phase 2 clinical trial in systemic lupus erythematosus expected to start second half 2021-Phase 1a results to be presented in a conference call scheduled today at 8:30 a.m. ET WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics (Nasdaq: PAND) today announced positive to
CAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer. Dr. Johns is an accomplished drug development leader and board-certified clinical neurologist who previously served as Chief Medical Officer and Executive Vice President of Medical and Scientific Affairs at Syntimmune, prior to the company’s acquisition by Alexion Pharmaceuticals. Ms. Dorton is a recognized
WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expe
CAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer. Dr. Johns is an accomplished drug development leader and board-certified clinical neurologist who previously served as Chief Medical Officer and Executive Vice President of Medical and Scientific Affairs at Syntimmune, prior to the company’s acquisition by Alexion Pharmaceuticals. Ms. Dorton is a recognized
WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expe
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp
SC 13G/A - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13D/A - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13D/A - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13D - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13D - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13G - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13G - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13G/A - Pandion Therapeutics, Inc. (0001807901) (Subject)
SC 13G - Pandion Therapeutics, Inc. (0001807901) (Subject)